CareDx Announces Closing of Public Offering of Common Stock
June 15, 2020
Palo Alto – Paul Hastings LLP, a leading global law firm, announced today that the firm represented CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, in an underwritten public offering (the “Offering”) of $125 million in shares of common stock. CareDx has granted the underwriters a 30-day option to purchase up to an additional approximately $18.75 million in shares, solely to cover over-allotments. CareDx intends to use the proceeds from the offering for working capital and general corporate purposes.
Goldman Sachs & Co. LLC and Jefferies LLC acted as joint book-running managers for the offering.
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.